In the field of bio-tech, it can take 10 years and millions of dollars to see if an experimental idea might turn into a life-saving treatment—if it ever does. Noubar Afeyan fully understood those risks when he co-founded Moderna in 2010. He and his colleagues were looking for a way to deploy the messenger RNA molecule to tackle life-threatening diseases. In January of 2020, an urgent opportunity presented itself in the form of a deadly virus that was spreading across the globe. At a breathtaking pace, Moderna produced a prototype for a COVID-19 vaccine, partnered with the NIH to test it, and produced millions of doses, becoming part of the most rapid vaccine roll-out in human history. While Moderna is the best known of Noubar’s companies, he has launched many others in the bio-tech space as part of Flagship Pioneering, his multi-billion dollar venture studio.
Moderna and Flagship Pioneering: Noubar Afeyan
By NPR
Oct 11, 2021 | 12:10 AM
Last Played
MoreTrending
Tupac Estate Threatens To Sue Drake Over Diss Track Using AI Vocals
7h ago
Taylor Swift's New Album Passes 1 Billion Spotify Streams, 1.8 Million In Sales
7h ago
Kid Cudi Cancels Upcoming Tour After Breaking Foot At Coachella
7h ago
New Single From Motley Crue Out Friday
7h ago
Train Drops New Single, Announces Live Album
7h ago
Last Played
MoreTrending
Tupac Estate Threatens To Sue Drake Over Diss Track Using AI Vocals
7h ago
Taylor Swift's New Album Passes 1 Billion Spotify Streams, 1.8 Million In Sales
7h ago
Kid Cudi Cancels Upcoming Tour After Breaking Foot At Coachella
7h ago
New Single From Motley Crue Out Friday
7h ago
Train Drops New Single, Announces Live Album
7h ago